Investors with a lot of money to spend have taken a bearish stance on CRISPR Therapeutics CRSP.
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CRSP, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 15 uncommon options trades for CRISPR Therapeutics.
This isn't normal.
The overall sentiment of these big-money traders is split between 40% bullish and 53%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $148,003, and 12 are calls, for a total amount of $571,849.
Expected Price Movements
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $40.0 to $75.0 for CRISPR Therapeutics over the recent three months.
Analyzing Volume & Open Interest
In terms of liquidity and interest, the mean open interest for CRISPR Therapeutics options trades today is 628.14 with a total volume of 1,152.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for CRISPR Therapeutics's big money trades within a strike price range of $40.0 to $75.0 over the last 30 days.
CRISPR Therapeutics Option Activity Analysis: Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CRSP | CALL | TRADE | BEARISH | 04/17/25 | $1.95 | $1.9 | $1.9 | $60.00 | $76.0K | 1.3K | 417 |
| CRSP | CALL | TRADE | BEARISH | 01/16/26 | $12.7 | $12.5 | $12.5 | $50.00 | $62.5K | 1.0K | 0 |
| CRSP | PUT | TRADE | NEUTRAL | 01/15/27 | $13.4 | $11.1 | $12.2 | $47.50 | $61.0K | 59 | 0 |
| CRSP | CALL | TRADE | BEARISH | 04/17/25 | $11.9 | $11.7 | $11.7 | $40.00 | $58.5K | 571 | 107 |
| CRSP | CALL | TRADE | BULLISH | 03/14/25 | $10.1 | $9.5 | $10.1 | $40.00 | $57.5K | 180 | 0 |
About CRISPR Therapeutics
Crispr Therapeutics AG is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Following our analysis of the options activities associated with CRISPR Therapeutics, we pivot to a closer look at the company's own performance.
Present Market Standing of CRISPR Therapeutics
- With a volume of 1,764,822, the price of CRSP is down -4.38% at $50.7.
- RSI indicators hint that the underlying stock may be approaching overbought.
- Next earnings are expected to be released in 76 days.
What The Experts Say On CRISPR Therapeutics
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $73.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * Consistent in their evaluation, an analyst from Morgan Stanley keeps a Underweight rating on CRISPR Therapeutics with a target price of $32. * An analyst from Truist Securities has decided to maintain their Buy rating on CRISPR Therapeutics, which currently sits at a price target of $120. * Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on CRISPR Therapeutics with a target price of $48. * An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $84. * An analyst from Citigroup has decided to maintain their Buy rating on CRISPR Therapeutics, which currently sits at a price target of $82.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for CRISPR Therapeutics, Benzinga Pro gives you real-time options trades alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
